These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 35084268)
1. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design. Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268 [TBL] [Abstract][Full Text] [Related]
2. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers. Pandey D; Chauhan SC; Kashyap VK; Roy KK Eur J Med Chem; 2024 Nov; 277():116771. PubMed ID: 39167893 [TBL] [Abstract][Full Text] [Related]
3. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Chen Y; Liu QP; Xie H; Ding J Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578 [TBL] [Abstract][Full Text] [Related]
4. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824 [TBL] [Abstract][Full Text] [Related]
5. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449 [TBL] [Abstract][Full Text] [Related]
6. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Parums DV Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327 [TBL] [Abstract][Full Text] [Related]
7. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors. Rathod LS; Dabhade PS; Mokale SN Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967 [TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Reck M; Carbone DP; Garassino M; Barlesi F Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836 [TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS in Colorectal Cancer. Wang C; Fakih M Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927 [TBL] [Abstract][Full Text] [Related]
10. More to the RAS Story: KRAS Lietman CD; Johnson ML; McCormick F; Lindsay CR Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303 [TBL] [Abstract][Full Text] [Related]
11. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531 [TBL] [Abstract][Full Text] [Related]
12. Targeting mutated GTPase KRAS in tumor therapies. Fan G; Lou L; Song Z; Zhang X; Xiong XF Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956 [TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196 [TBL] [Abstract][Full Text] [Related]